Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Narcolepsy - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H1 2017, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape. Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 3, 2, 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively. Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Narcolepsy - Overview Narcolepsy - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Narcolepsy - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Narcolepsy - Companies Involved in Therapeutics Development Avadel Pharmaceuticals Plc Bioprojet SCR Evotec AG H.A.C. Pharma Heptares Therapeutics Ltd Jazz Pharmaceuticals Plc Ono Pharmaceutical Co Ltd OptiNose US Inc Reset Therapeutics Inc Sanofi SK Biopharmaceuticals Co Ltd Taisho Pharmaceutical Holdings Co Ltd Theranexus SAS Narcolepsy - Drug Profiles (flecainide acetate + modafinil) - Drug Profile Product Description Mechanism Of Action R&D Progress arbaclofen - Drug Profile Product Description Mechanism Of Action R&D Progress JZP-258 - Drug Profile Product Description Mechanism Of Action R&D Progress JZP-386 - Drug Profile Product Description Mechanism Of Action R&D Progress JZP-507 - Drug Profile Product Description Mechanism Of Action R&D Progress LGD-3437 - Drug Profile Product Description Mechanism Of Action R&D Progress mazindol - Drug Profile Product Description Mechanism Of Action R&D Progress mazindol CR - Drug Profile Product Description Mechanism Of Action R&D Progress ONO-4127 - Drug Profile Product Description Mechanism Of Action R&D Progress OPN-21 - Drug Profile Product Description Mechanism Of Action R&D Progress pentylenetetrazol - Drug Profile Product Description Mechanism Of Action R&D Progress pitolisant - Drug Profile Product Description Mechanism Of Action R&D Progress SAR-110068 - Drug Profile Product Description Mechanism Of Action R&D Progress SKL-N05 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize Orexin Receptor for Narcolepsy and Sleep Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress sodium oxybate - Drug Profile Product Description Mechanism Of Action R&D Progress sodium oxybate - Drug Profile Product Description Mechanism Of Action R&D Progress TS-091 - Drug Profile Product Description Mechanism Of Action R&D Progress YNT-185 - Drug Profile Product Description Mechanism Of Action R&D Progress Narcolepsy - Dormant Projects Narcolepsy - Discontinued Products Narcolepsy - Product Development Milestones Featured News & Press Releases Apr 26, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 2 Study of JZP-110 in Narcolepsy Patients with Excessive Sleepiness Apr 24, 2017: Jazz Pharmaceuticals Announces Positive Results from the Phase 2/3 EXPRESS Study of Xyrem in Pediatric Patients with Narcolepsy with Cataplexy Mar 15, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy Feb 13, 2017: Lincoln Medical's Wakix Rejects For Use Within NHS Scotland Jan 25, 2017: A New Study Published by The Lancet Neurology Shows Efficacy of Pitolisant (Wakix) on Cataplexy in Patients with Narcolepsy Dec 16, 2016: Flamel Technologies Doses First Patient in REST-ON Phase III Trial of FT218 for Excessive Daytime Sleepiness & Cataplexy Nov 28, 2016: Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy Oct 27, 2016: Inclusion of the First Patient in the Phase II Clinical Study That Aims to Test THN102 in Patients Affected by Narcolepsy Oct 06, 2016: Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III Pivotal Trial of FT218 Oct 04, 2016: Theranexus Has Obtained an Orphan Drug Designation from the FDA for THN102 in the Treatment of Narcolepsy Jul 11, 2016: Mazindol Granted Orphan Drug Designation in the US & Europe for Treatment of Narcolepsy Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting May 17, 2016: Theranexus Reaches Its Primary Endpoint in the Proof of Concept Trial of THN102 in Excessive Daytime Sleepiness Mar 31, 2016: Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Narcolepsy, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Narcolepsy - Pipeline by Avadel Pharmaceuticals Plc, H1 2017 Narcolepsy - Pipeline by Bioprojet SCR, H1 2017 Narcolepsy - Pipeline by Evotec AG, H1 2017 Narcolepsy - Pipeline by H.A.C. Pharma, H1 2017 Narcolepsy - Pipeline by Heptares Therapeutics Ltd, H1 2017 Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H1 2017 Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Narcolepsy - Pipeline by OptiNose US Inc, H1 2017 Narcolepsy - Pipeline by Reset Therapeutics Inc, H1 2017 Narcolepsy - Pipeline by Sanofi, H1 2017 Narcolepsy - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017 Narcolepsy - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017 Narcolepsy - Pipeline by Theranexus SAS, H1 2017 Narcolepsy - Dormant Projects, H1 2017 Narcolepsy - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
